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Long-term effects of chemotherapy on lymphocyte
chromosomes from patients treated for gestational
trophoblastic tumours
B.R. Reeves, S.D. Lawler, G. Casey & H. Harris
Section ofHuman Genetics, Institute of Cancer Research, Royal Marsden Hospital, Fulham Road, London
SW3 6JJ, UK.
Summary A cytogenetic follow-up study of patients treated with chemotherapy for gestational trophoblastic
tumours was undertaken. In some cases, high levels of chromosome damage were found to persist in
lymphocytes for several years after completion of therapy. These results are compared with those found in
similar studies of non-malignant and other malignant diseases. The relevance of these findings to the risk of
subsequent chemotherapy-induced malignancy is discussed.
Some patients treated by chemotherapy for benign
or malignant diseases are subsequently at risk for
the development of a primary (Grunwald & Rosner
1979) or secondary malignancy (Chabner, 1977).
Cytotoxic drugs can act as mutagens or
carcinogens. Chromosome damage is recognised as
being a sensitive biological indicator of exposure to
physical or chemical mutagens/carcinogens (Wolff,
1982) and this genotoxic effect can be be measured
in peripheral blood lymphocytes, bone marrow and
other tissues. Our earlier study of patients during
and shortly after receiving chemotherapy for a
gestational trophoblastic tumour (GTT) showed
that although very little chromosomal damage was
observed with some of the regimes, intensive
chemotherapy did have some effects (Lawler &
Walden, 1978). We now report a review and follow-
up (at least 5 years after the chemotherapy ended)
of some of the patients examined in our previous
study and serial studies of a patient who had
received ten courses of intensive chemotherapy
more than 3 years previously.
Patients and methods
The patients were females aged between 21 and 37
years when treated at the Charing Cross Hospital,
London. All but one of them had a GTT and the
therapy was monitored by measuring levels of
human chorionic gonadotrophin (HCG). The
exceptional patient, No. 519, had a dysgerminoma
of the ovary that secreted HCG. Patients with
trophoblastic tumours were assigned to low,
medium or high-risk categories, according to
Correspondence: B.R. Reeves.
Received 11 February 1985; and in revised form 3 July
1985.
prognostic factors (Bagshawe, 1976). Low risk
patients were given courses of methotrexate (50mg)
on alternate days x4, with folinic acid 30h after
each injection of methotrexate. A treatment course
of 8 days was followed by a rest period of 7 days.
Medium risk patients received four or more drugs
in a series of courses of 3-8 days duration, but
usually not more than two drugs were given in each
course. These drugs included methotrexate, 6
azouridine, hydroxyurea, actinomycin D, cytosine
arabinosode, vincristine, cyclophosphamide, adria-
mycin, chlorambucil and bleomycin. Not all
patients received all the drugs and rest periods
between courses were from 7-10 days.
Patient no. 519, with highly unfavourable
prognostic features, was treated with a regimen that
included 7 or 8 of the drugs listed for the medium
risk patients, in courses of 6-9 days. The interval
between successive courses was 10-20 days. In
order to increase the observations of the effects of
intensive chemotherapy a patient in the high risk
group (No. 975), treated in 1980 with 3 courses of
CHAMOCA and 7 courses of the EMA-Co
protocol which contains etoposide in addition to
the drugs listed above (Bagshawe, 1984), was
included in the study.
All the patients were well and in remission at the
time of the follow-up chromosome studies.
Peripheral blood (PB) lymphocyte cultures were set
up from heparinised whole blood as follows:
0.4mlPB, 8mlTC199, 2mlAB serum (1st study) or
2ml foetal calf serum (2nd study), 0.1ml phyto-
haemagglutinin (PHA) (Wellcome, Reagent grade).
The cultures were incubated at 37°C and terminated
at 48 or 72h, following 1.5h exposure to 2,ugml-1
colcemid. In the first study the chromosomes were
stained with Giemsa but were not banded. One
hundred lymphocytes were scored for the presence
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of gaps, breaks, fragments and abnormal
chromosomes. In the follow-up study the
chromosomes were Giemsa-banded using a
modification of the technique of Gallimore &
Richardson (1973). The cells were analysed and the
chromosome abberations were scored using
standard criteria (ISCN 1978). For cell kinetic and
sister-chromatid exchange (SCE) studies, cultures
containing 2 pugml-1 5-bromo-2'-deoxyuridine were
incubated in the dark, harvested and spread onto
slides in the usual way. Cells were then stained
using a modification of the FPG method of Perry
& Wolff (1974).
Results
The results of a review of the earlier studies of the
unbanded chromosomes of the patients in the long-
term follow-up investigation are given in Table I.
There are four patients in both the low and
medium risk categories and one in the high risk.
The chromosomal damage has been expressed as
the number of gaps and/or breaks per cell; on our
laboratory for normal controls the number ranges
from 0-0.06 in 48h cultures. Thus the only patient
with a raised level (no. 519) was in the high risk
category.
Between 6 and 9 years after the completion of
chemotherapy, further samples of the peripheral
blood lymphocytes from these patients were
obtained and the chromosomes examined following
Giemsa-banding. The results of these tests are
shown in Table II.
It is apparent that there is individual variation
between patients in the frequency of chromosome
abnormalities, and also that the frequency is
influenced by the time that the lymphocytes are in
culture. In 48h cultures made with TC199, our
laboratory normal controls have 3.4%-6.0%
abnormal cells. Of these, 0-4.0% have simple
breaks or gaps, 0-2.0% are aneuploid/rearranged
and the value for total breaks gaps per cell is 0-
0.06. The corresponding figures for 72h cultures
are: -2.2%-6.25% abnormal cells, 0-6.25% simple
breaks/gaps, 0-2.2% aneuploid/rearranged and
0.04-0.06 total breaks/gaps per cell. Simple
Table I Studies of unbanded chromosomes in 48h peripheral blood
lymphocyte cultures before chemotherapy and after treatment. 100 cells
examined at each time.
Post-treatment
Case no.
risk Pre-treatment No. of Weeks after
category' brlg/cell courses treatment br/g/cell
394 0.01 2 1 0.0
Low
395 0.04 5 2 0.03
Low
402 0.03 3 6 0.01
Low
410 0.0 5 6 0.02
Low
401 0.02 9 10 0.02
Medium
407 0.02 8 5 0.0
Medium
489 NT 17 6 0.01
Medium
538 0.04 9 6 0.0
Medium
519 NT 11 18 O.1b
High
aSee text; bAbove upper limit of controls; br-breaks; g-gaps; NT-not
tested.CHROMOSOME STUDIES IN CHEMOTHERAPY PATIENTS 721
C en l 00
00 0- 00a
1 = =
IeA =
I -
O I--,
0 0 ene 1-
eIR
Cl
e0N -
en
- -4
Cl0 0-.
O 0 C1 ON 'IC
A D0
O0 00 00 _
I-I
O O te) C1 _ 1%
6-4
ClCF,l 000 00006
as en as 14 WI
en-W) l-o en 1.,
" " cc ol 00 00
C0
C0 00
IfC .0 A0
A
WI eq A 00 r-
O) O4 1-0 O0 O 0 00 00l 000
c1 15
=
0
0
a
0
I-,
0 Cl4
00C 00 l 00C 00
N- 00 00
A A
0 em
wri 4j
-0
_ O-10
A
O 4
0 0 00
.0.0.
A A
O C- en 00
C1 en o en o _#
.0A .0 .0
00i4 :cl0
I--, ---,
.0 .0
O 0e
0--
t 0 Cl4en 00
0" Cl C'C t-
Oo0 00Cl 00 l 00
C- O
~00
00
4)~~~()
- ( l
4.) 00 4() a,
-~ oN 0
A
V4
\V
En
:-_
(4)
Q
-0
0
Q
0 s
U
E
04
C)
4)
w
o
4L) -4
4)
4-
0
0
0
C)
"0 4)
"0
0.
w
4)
"0
r-
;Y
0
E
._
q
0 Ct
Cd
._
C.
U0
00
C-
00
- E; 4t
o.
.2 m
_ 11
-4)
0
4)-
Co
.D*G CC > - 11
10 11
I 0
0 U
C'd
o
D2 0
00
4).-
.0 O
O)"
; 0 =
c4 *_
001
0o
's
S: (Z
14i i 11 1 u
Q t3722 B.R. REEVES et al.
numerical changes were not found in our series of
controls.
Six of the 9 natients in Table II had a hiQher o . frequently of abnormal cells than the controls
(P= <0.05), Wilcoxon-Mann-Whitney test). No
clones were observed and each ofthe rearrangements
was unique. (Patient no. 402 had a fragile site at
10q23 and these lesions have not been included in
the Tables). Simple breaks or gaps were the most
common chromosome abnormalities found in the
, ~ *~controls, while the majority of abnormalities found
Cd >.. in the patients in the low and medium-risk groups
were breaks and deletions; the breakpoints beihg
distributed at random. In patient 519 (high-risk) a
balanced translocation was found in addition to
11 o simple breaks and deletions.
In addition to the rearrangements arising by
chromosome breakage, abnormal cells arising by
loss or gain of whole chromosomes were identified
in three patients, 402, 410 and 489. A raised
CZ efrequency of gaps/breaks per cell was found in at
II en 11 ,least 1 culture from patients 394, 402 (low-risk),
407, 489 (medium-risk) and 519 (high-risk)
E r O; although only in no 519 had a raised frequency
Z g gLz been found when they were examined within weeks
II =o 11 ofcompleting chemotherapy.
r^^° Details of vatient 975 (high risk categorv) are
00 rgiven in Table III. No rearranged cells were
1 ^ 0 observed in the pretreatment sample, but the
Cd - .Dnumber of simple gaps/breaks in the 72h culture
Cd t ,<: was raised. Seven months after the cessation of
chemotherapy the frequency of gaps/breaks (0.15)
r-4-O rAwas still raised; 33 months later the number had
U = (>, increased to 0.35 per cell. The frequency of
> 11 rearranged cells was also raised in both post-
11 treatment tests, and it is important to note that in
-< ^ G addition to simple deletions a dicentric chromo-
;,,^.=^ n some was observed.
o4 Among our control subjects the mean frequency
4 of SCEs in PHA stimulated lymphocytes is 10.1 per
cell (range 8.1-13.3) and the numbers found in the
patients were all within these limits.
ce ;-,
E Discussion
0 Q ,a
In the patients reported here, there was generally a
21 1I higher frequency of chromosomal lesions in the
lymphocytes studied between 5 and 9 years after
0_ : treatment than there was within a few months of
therapy. However, we cannot exclude the possibility
that some small deletions or translocations may not
-, ° =have been detected in the earlier study on unbanded
chromosomes. Some lymphocytes have a life span 0. .4 OImany yrars; tlns suggests tne possibiiity that tte
damaged cells observed in the follow-up study were
sequestered at the time of treatment, or soon after,
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and that they subsequently re-entered the
circulating lymphocyte pool.
Although there was some variation between
patients, more persistent chromosome damage was
generally found within the medium and high-risk
groups. Among our controls, the majority of
abnormalities were simple breaks or gaps. However,
in the patients, cells with deletions (or more
complex structural abnormalities) and numerical
changes contributed substantially to the numbers of
abnormal cells; the most complex changes occurring
in the two intensively-treated patients in the high-
risk category (nos. 519 and 975).
For the measurement of chromosome damage it
is preferable to examine cells in their first division
in vitro. The majority of cells in 48h cultures were
in first division, but the percentage of cells in first
division was lower at 72h in all patients in whom
cultures were made at both times. It is possible
therefore, that some of the lesions observed when
the culture time was extended to 72h could have
arisen in vitro.
Some chromosome changes are known to be
important in the initiation or progression of
malignancy. However, it is not yet clear how the
presence of chromosome abnormalities in the
lymphocytes of patients treated with cytotoxic
agents for benign or malignant conditions, relates
to the risk of developing a subsequent neoplasm.
For example, when chlorambucil is used in
continuous or intermittent schedules for the
treatment of non-malignant disorders, there is an
increased risk of the development of leukaemia
(reviewed by Palmer et al., 1984). Among a series
of patients with uveitis treated with chlorambucil,
we found some to have chromosome damage
persisting for many years after the cessation of
therapy (Reeves et al., submitted for publication)
but there is as yet no case of malignancy recorded
among them.
Lambert et al. (1984) studied a group of 50
patients with ovarian carcinoma treated with
melphalan, in some cases combined with
radiotherapy, and found high levels of chromosome
aberrations persisting for up to 8 years after
treatment. Patients on this treatment protocol are
known to be at risk of developing secondary
leukaemia (Einhorn et al., 1982). However, no case
of leukaemia had been found by Lambert et al.,
although one patient (who had also received
radiotherapy) developed a gastric carcinoma 5 years
after completing therapy.
We have found evidence in this study for the
persistence of genotoxic damage many years after
the completion of successful chemotherapy.
However, Rustin et al. (1983) have reported that
patients treated for GTT do not have an increased
risk of developing a subsequent malignancy at
another site. The treatment protocols for GTTs are
based on regular intermittent schedules over a mean
period with no maintenance, and Rustin et al. have
suggested that this method of giving therapy might
be an important factor contributing to the lack of
risk. However, it must also be borne in mind that
these trophoblastic tumours are genetically foreign
to the host, whereas in patients with tumours
derived from host tissue, genetic susceptibility could
account for or contribute to the occurrence of
second tumours.
We thank Professor K.D. Bagshawe and othr consultant
staff for permission to study patients treated in the
Department of Medical Oncology, Charing Cross
Hospital, London, Mr G.J. Swansbury for statistical
advice and Miss M. Afonso for preparing the manuscript.
The study was supported by the Cancer Research
Campaign.
References
BAGSHAWE, K.D. (1976). Risk and prognostic factors in
trophoblastic neoplasia. Cancer, 38, 1373.
BAGSHAWE, K.D. (1984). Management of high risk
choriocarcinoma. J. Reprod. Med., 29, 813.
CHABNER, B.A. (1977). Second neoplasm - a complication
of cancer chemotherapy. New Engl. J. Med., 297, 213.
EINHORN, N., EKLUND, G., FRANZPN, S., LAMBERT, B.,
LINDSTEN, J., & SODERHALL, S. (1982). Late side
effects of chemotherapy in ovarian carcinoma. Cancer,
49, 2234.
GALLIMORE, P.H. & RICHARDSON, C.R. (1973). An
improved banding technique exemplified in the
karyotype analysis of two strains of rat. Chromosoma,
41, 259.
GRONWALD, H.W. & ROSNER, F. (1979). Acute leukemia
and immunosuppressive drug use. Arch. Intern. Med.,
139, 461.
ISCN (1978). An international system for human
cytogenetic nomenclature (1978). Cytogenet, Cell
Genet., 21, 309.
LAMBERT, B., HOLMBERG, K. & EINHORN, N. (1984).
Persistence of chromosome rearrangements in
peripheral lymphocytes from patients treated with
melphalan for ovarian carcinoma. Hum. Genet., 67, 94.724 B.R. REEVES et al.
LAWLER, S.D. & WALDEN, P.A.M. (1978). Chromosome
studies in patients treated with chemotherapy for
trophoblastic tumours. In Mutagen-induced chromo-
some damage in man. Evans & Lloyd (eds) p. 239.
University Press, Edinburgh.
PALMER, R.G., DORE, C.J. & DENMAN, A.M. (1984).
Chlorambucil-induced chromosome damage to human
lymphocytes is dose-dependent and cumulative.
Lancet, i, 246.
PERRY, P., & WOLFF, S. (1974). New Giemsa method for
the differential staining of sister chromatid exchanges.
Nature, 251, 156.
RUSTIN, G.J.S., RUSTIN, F., DENT, J., BOOTH, M., SALT,
S. & BAGSHAWE, K.D. (1983). No increase in second
tumors after cytotoxic chemotherapy for gestational
trophoblastic tumors. New Engl. J. Med., 308, 473.
WOLFF, S. (1982). Difficulties in assessing the human
health effects of mutagenic analyses. Cytogenet. Cell
Genet., 33, 7.